Lixte Biotechnology Holdings, Inc Lixt Stock saw a decline in short interest in June. Last month, there was short interest totaling 23,500 shares, a drop of 20.3% from the June 15th total of 29,500 shares.
Currently, 0.3% of the company’s shares are sold short. A short-interest ratio of 0.0 days is calculated based on an average daily volume of 3,590,000 shares.
Hedge Funds Give Their Take On Lixt Stock
Regarding lixt stock news, recently, An institutional investor took a new position in Lixte Biotechnology stock. In addition, EP Wealth Advisors LLC made a new position in Lixte Biotechnology Holdings, Inc shares.
The company reported its latest filing to the Securities and Exchange Commission during the first quarter. A $31,000 institutional investor purchased 25,025 shares of the company’s stock.
EP Wealth Advisors LLC owned about 0.15% of Lixte Biotechnology as its most recent SEC filing. Institutional investors and hedge funds own 8.82% lixt stock.
Lixte Biotechnology’ Stock Lixt’ Price Performance
Lixt stock price opened at $0.785 on Wednesday. The company has a market valuation of $13.64 million, a PE ratio of -1.67, and a beta of -1.12. The company has a 50-day moving average (MA) of $0.79 and a 200-day moving average (MA) of $1.26. Lixte Biotechnology has a 1-year lowest price of $0.66 and a 1 year high of $4.95.
Lixte Biotechnology Inc last announced its quarterly earnings results on Wednesday, May 11th. The company posted ($0.12) earnings per share for the quarter.
Lixt Stock Forecast
In order to analyze ‘Lixt Stock Forecast’, we must consider two perspectives; one is short-term and the other long-term.
Based on the current short-term trend, the lixt stock is projected to fall -by 28.00% over the next 3 months and, with a 90% possibility, hold a price between $0.35 and $0.85 by the end of these 3 months.
And based on the long-term forecast massive increase is expected, the Lixt stock price estimate for 2027-07-14 is 2.976 USD. Therefore, with a 5-year investment, the revenue is projected to be about +262.97%.
Lixte Biotechnology Inc Company Profile
Lixte Biotechnology Holdings, Inc. works as a drug discovery company to identify enzyme targets related to serious common diseases and create novel compounds that attack them.
In addition to inhibitors of protein phosphatases, the company develops x-ray and immune checkpoint blockers and cytotoxic agents at various phases of preclinical and clinical development.
FAQs on Lixt Stock
How to buy shares of Lixte Biotechnology Inc ?
Follow the steps below to buy the Lixte Stock:
- Sign-up for an Exchange or Broker Account.
- Confirm your payment details. Add Funds to your account.
- Search for the Lixt stock by name or ticker symbol (ATHA).
- From now on, you can make a spot order or even can trade on margin.
Is Lixte Biotechnology Inc. a good stock to buy?
As of now, short-term market sentiment and technical analysis for Lixt Stock is bearish, but long-term, it’s a great buy.
What are the predictions for Lixte Biotechnology Inc. (Lixt) stock?
Analysts predicted that with all the biotech boom, Lixt stock is projected to increase 262.97% over the next 5 years.
As for the short term, Lixt Stock is heading at lower prices, but from the long run perspective, it’s a good stock to hold in your portfolio and one of the best in the biotech sector.